An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Chemotherapy regimens associated with MabThera/Rituxan in management of relapse/refractory CLL: Percentage of patients receiving purine analogues/bendamustine/alkylating agents/other chemotherapy [ Time Frame: 2 years ]
Secondary Outcome Measures
Overall response rate [ Time Frame: 2 years ]
Complete response rate [ Time Frame: 2 years ]
Progression-free survival [ Time Frame: 2 years ]
Time to next treatment [ Time Frame: 2 years ]
Overall survival [ Time Frame: 2 years ]
Safety (incidence of adverse events) [ Time Frame: 2 years ]
Safety (incidence of hematologic adverse events) [ Time Frame: 2 years ]
Safety (incidence of infections) [ Time Frame: 2 years ]
Safety (incidence of secondary malignancies) [ Time Frame: 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult patients with relapsing or refractory chronic lymphocytic leukemia (CLL)
Adult patients, >/=18 years of age
Diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) with first or second relapse
Previous treatment with MabThera/Rituxan
MabThera/Rituxan treatment planned for current relapse